FDA warned India-based www.wellerectile.com over selling unapproved, improperly labeled drugs online, including hydroxychloroquine claimed to treat COVID-19.
What happened
FDA reviewed the website www.wellerectile.com on February 7, 2022 and found it offered drugs for sale to U.S. consumers, including Hydroxychloroquine Tablets IP HCQS-200 promoted as effective for COVID-19. FDA said the products are unapproved new drugs (drugs without FDA approval) and misbranded (improperly labeled) because the prescription drug labeling lacks adequate directions for use.
What FDA found
The website offers drug products for sale in the U.S. without FDA-approved applications.
section 505(a) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 355(a)]Hydroxychloroquine Tablets IP HCQS-200 made by IPCA is promoted as effective for COVID-19, but FDA has not approved hydroxychloroquine for COVID-19.
section 505(a) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 355(a)]The prescription drug's labeling does not give adequate directions for safe use by a layperson.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]The company causes an improperly labeled drug to be introduced into interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]The company introduces or delivers unapproved new drugs into interstate commerce.
sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. § 331(d), § 355(a)]
What FDA wants
Within 48 hours, email FDA at the listed addresses to describe steps taken to correct the violations and prevent recurrence, with supporting documents; if corrections cannot be completed in 48 hours, state why and when they will be done.
Who should pay attention
- foreign online pharmacies selling to U.S. consumers
- companies marketing hydroxychloroquine or COVID-19 treatments
- platforms hosting ads for prescription drugs
This is a summary. Read the original letter on fda.gov.